IP Library Granted Patent US 11,958,809
Granted Patent B2
US 11,958,809 · App. 17/448,833 · Granted Apr 16, 2024

Salt of omecamtiv mecarbil and process for preparing salt

Inventors: Sheng Cui (Thousand Oaks, CA); Henry Morrison (Thousand Oaks, CA); Karthik Nagapudi (South San Francisco, CA); Shawn D. Walker (Woodland Hills, CA); Charles Bernard (Moorpark, CA); Karl Bennett Hansen (Cohasset, MA); Neil Fred Langille (Thousand Oaks, CA); Alan Martin Allgeier (Wilmington, DE); Steven M. Mennen (Thousand Oaks, CA); Jacqueline C. S. Woo (Sherwood Park, CA); Bradley Paul Morgan (Moraga, CA); Alex Muci (San Francisco, CA)
Assignee: CYTOKINETICS, INC.
C07D213/75A61K9/2013A61K9/2018A61K9/2054A61K31/496A61K47/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,958,809
App. No.
17/448,833
Granted
Apr 16, 2024
Kind
B2
Abstract

Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.

Claims (46)

1. A method of preparing omecamtiv mecarbil dihydrochloride hydrate

comprising:

step (a) admixing methyl 4-(3-amino-2-fluorobenzyl)piperazine-1-carboxylate (Piperazine Aniline)

and phenyl (6-methylpyridin-3-yl)carbamate (Phenyl Carbamate·HCl)

in the presence of diisopropylethylamine and THF to form a solution of omecamtiv mecarbil free base;

step (b) swapping solvent of the solution of omecamtiv mecarbil free base to 2-propanol;

step (c) admixing the solution of omecamtiv mecarbil free base with hydrochloric acid in the presence of water to form omecamtiv mecarbil dihydrochloride hydrate.

2. The method of claim 1 , wherein the methyl 4-(3-amino-2-fluorobenzyl) piperazine-1-carboxylate (Piperazine Anilline)

is prepared by a process comprising:

step (i) neutralizing methyl 4-(2-fluoro-3-nitrobenzyl)piperazine-1-carboxylate hydrochloride (Piperazine Nitro·HCl)

with sodium bicarbonate in water and isopropyl acetate to yield methyl 4-(2-fluoro-3-nitrobenzyl)piperazine-1-carboxylate

step (ii) hydrogenating methyl 4-(2-fluoro-3-nitrobenzyl)piperazine-1-carboxylate in the presence of palladium on carbon in isopropyl acetate to form methyl 4-(3-amino-2-fluorobenzyl)piperazine-1-carboxylate;

step (iii) isolating methyl 4-(3-amino-2-fluorobenzyl)piperazine-1-carboxylate from isopropyl acetate and heptane.

3. The method of claim 2 , wherein methyl 4-(2-fluoro-3-nitrobenzyl) piperazine-1-carboxylate hydrochloride

is prepared by a process comprising:

Step (i) admixing 2-fluoro-3-nitrotolune (FN-Toluene)

with N-bromosuccinimide, benzoyl peroxide, and acetic acid to form a mixture of 1-(bromomethyl)-2-fluoro-3-nitrobenzene (FN-Bromide)

and 1-(dibromomethyl)-2-fluoro-3-nitrobenzene (Dibromide)

Step (ii) contacting the mixture of FN-bromide and Dibromide with diethylphosphite and diisopropylethylamine in methanol to form a solution of FN-bromide;

Step (iii) admixing the solution of FN-bromide with diisopropylethylamine, and piperazine carboxylate

in toluene to form a solution of Piperazine Nitro free base

and

Step (iv) admixing the solution of Piperazine Nitro free base with IPA, water, and HCl to form methyl 4-(2-fluoro-3-nitrobenzyl)piperazine-1-carboxylate hydrochloride.

4. The method of claim 1 , wherein the phenyl (6-methylpyridin-3-yl)carbamate (Phenyl Carbamate·HCl)

is prepared by admixing Amino Pyridine

with phenyl chloroformate in acetonitrile and N-methyl-2-pyrolidinone.

5. A method of preparing omecamtiv mecarbil dihydrochloride hydrate

comprising:

step (i) admixing 2-fluoro-3-nitrotolune (FN-Toluene)

with N-bromosuccinimide, benzoyl peroxide, and acetic acid to form a mixture of 1-(bromomethyl)-2-fluoro-3-nitrobenzene (FN-Bromide)

and 1-(dibromomethyl)-2-fluoro-3-nitrobenzene (Dibromide)

step (ii) contacting the mixture of FN-bromide and Dibromide with diethylphosphite and diisopropylethylamine in methanol to form a solution of FN-bromide;

step (iii) admixing the solution of FN-bromide with diisopropyethylamine, and piperazine carboxylate

in toluene to form a solution of Piperazine Nitro free base

step (iv) admixing the solution of Piperazine Nitro free base with IPA, water, and HCl to form methyl 4-(2-fluoro-3-nitrobenzyl)piperazine-1-carboxylate hydrochloride (Piperazine Nitro·HCl)

wherein the method further comprises:

step (v) neutralizing the methyl 4-(2-fluoro-3-nitrobenzyl)piperazine-1-carboxylate hydrochloride (Piperazine Nitro·HCl) prepared from steps (i)-(iv) with sodium bicarbonate in water and isopropyl acetate to yield methyl 4-(2-fluoro-3-nitrobenzyl)piperazine-1-carboxylate

step (vi) hydrogenating methyl 4-(2-fluoro-3-nitrobenzyl)piperazine-1-carboxylate in the presence of palladium on carbon in isopropyl acetate to form methyl 4-(3-amino-2-fluorobenzyl)piperazine-1-carboxylate;

step (vii) isolating methyl 4-(3-amino-2-fluorobenzyl)piperazine-1-carboxylate from isopropyl acetate and heptane;

wherein the method further comprises:

step (viii) admixing Amino Pyridine

with phenyl chloroformate in acetonitrile and N-methyl-2-pyrolidinone to yield phenyl (6-methylpyridin-3-yl)carbamate (Phenyl Carbamate·HCl)

and wherein the method further comprises:

step (ix) admixing the methyl 4-(3-amino-2-fluorobenzyl)piperazine-1-carboxylate prepared from steps (v)-(vii) and the phenyl (6-methylpyridin-3-yl)carbamate from step (viii) in the presence of diisopropylethylamine and THF to form a solution of omecamtiv mecarbil free base;

step (x) swapping solvent of the solution of omecamtiv mecarbil free base to 2-propanol; and

step (xi) admixing the solution of omecamtiv mecarbil free base with hydrochloric acid in the presence of water to form omecamtiv mecarbil dihydrochloride hydrate.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2021
From: ALLGEIER, ALAN MARTIN; BERNARD, CHARLES; CUI, SHENG; HANSEN, KARL BENNETT; LANGILLE, NEIL FRED; MENNEN, STEVEN; MORRISON, HENRY; NAGAPUDI, KARTHIK; WALKER, SHAWN D.; WOO, JACQUELINE C.S.
To: AMGEN INC.
Reel/Frame 057785/0779 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2021
From: AMGEN INC.
To: CYTOKINETICS, INC.
Reel/Frame 057785/0805 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2021
From: MORGAN, BRADLEY PAUL; MUCI, ALEX
To: CYTOKINETICS, INC.
Reel/Frame 057909/0608 →
Continuity (7)
Continuation 17176003 · Feb 15, 2021
Continuation 16920155 · Jul 2, 2020
Continuation 16684216 · Nov 14, 2019
Continuation 15963529 · Apr 26, 2018
Division 14773436
Provisional Application 61785763 · Mar 14, 2013
Related Publication 20220153700A1 · May 19, 2022
Cited By (9)
US 12,194,039 US 12,221,417 US 12,264,133 US 12,269,811 US 12,275,704 US 12,295,952 US 12,442,027 US 12,583,821 US 12,612,366